The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study.
 
Ghayas C. Issa
No Relationships to Disclose
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
 
Nicholas James Short
No Relationships to Disclose
 
Farhad Ravandi
No Relationships to Disclose
 
Xuelin Huang
No Relationships to Disclose
 
Guillermo Garcia-Manero
No Relationships to Disclose
 
William Plunkett
No Relationships to Disclose
 
Varsha Gandhi
No Relationships to Disclose
 
Naveen Pemmaraju
No Relationships to Disclose
 
Naval Guastad Daver
No Relationships to Disclose
 
Gautam Borthakur
No Relationships to Disclose
 
Nitin Jain
No Relationships to Disclose
 
Marina Konopleva
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Abbvie; Calithera Biosciences; Genentech
Consulting or Advisory Role - AbbVie
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Stemline Therapeutics (Inst)
 
Zeev Estrov
No Relationships to Disclose
 
Tapan M. Kadia
No Relationships to Disclose
 
Courtney Denton Dinardo
Honoraria - Agios; Daiichi Sankyo; Novartis
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo; Novartis
 
Mark Brandt
No Relationships to Disclose
 
Susan Mary O'Brien
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen; Pfizer; Pharmacyclics; ProNAi; Regeneron; Sunesis Pharmaceuticals; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Amgen Astellas BioPharma; Aptose Biosciences; Celgene; CLL Global Research Foundation; GlaxoSmithKline; Janssen Oncology; Sunesis Pharmaceuticals; Vaniam Group
Research Funding - Acerta Pharma; Gilead Sciences; Pfizer; Pharmacyclics; ProNAI; Regeneron; TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; ARIAD; BiolineRx; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Teva (Inst)
 
Elias Jabbour
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer